Journal: Annals of Neurology; September 1, 2022
Author(s): Frederike Cosima Oertel, Elias S Sotirchos, Hanna G Zimmermann, Seyedamirhosein Motamedi, Svenja Specovius, Eva Susanna Asseyer, Claudia Chien, Lawrence Cook, Eleni Vasileiou, Angeliki Filippatou, Peter A Calabresi, Shiv Saidha, Lekha Pandit, Anitha D'Cunha, Olivier Outteryck, Hélène Zéphir, Sean Pittock, Eoin P Flanagan, M Tariq Bhatti, Paulus S Rommer, Gabriel Bsteh, Tobias Zrzavy, Tania Kuempfel, Orhan Aktas, Marius Ringelstein, Philipp Albrecht, Ilya Ayzenberg, Thivya Pakeerathan, Benjamin Knier, Lilian Aly, Nasrin Asgari, Kerstin Soelberg, Romain Marignier, Caroline Froment Tilikete, Alvaro Cobo Calvo, Pablo Villoslada, Bernardo Sanchez-Dalmau, Elena H Martinez-Lapiscina, Sara Llufriu, Ari J Green, Michael R Yeaman, Terry J Smith, Alexander U Brandt, John Chen, Friedemann Paul, Joachim Havla; with the GJCF International Clinical Consortium for NMOSD and the CROCTINO study group
Evaluation of long-term damage to the retina in MOGAD patients
Journal: Frontiers in Neurology; September 15, 2023
Author(s): Jyh Yung Hor, Kazuo Fujihara
How common is MOGAD worldwide?
Journal: Neurology Neuroimmunology & Neuroinflammation; November 17, 2023
Author(s): Mirasol Forcadela, Chiara Rocchi, Daniel San Martin, Emily L Gibbons, Daniel Wells, Mark R Woodhall, Patrick J Waters, Saif Huda, Shahd Hamid
Accurate diagnosis of MOGAD relies on the timing of antibody tests
Journal: Neurology Neuroimmunology & Neuroinflammation; March 26, 2021
Author(s): Romain Marignier, Jeffrey L. Bennett, Ho Jin Kim, Brian G. Weinshenker, Sean J. Pittock, Dean Wingerchuk, Kazuko Fujihara, Friedemann Paul, Gary R. Cutter, Ari J. Green, Orhan Aktas, Hans-Peter Hartung, Fred D. Lublin, Ian M. Williams, Jorn Drappa, Dewei She, Daniel Cimbora, William Rees, Michael Smith, John N. Ratchford, Eliezer Katz, Bruce A.C. Cree
Clinical trial paper on the effect of inebilizumab on disability outcomes in NMOSD
Journal: CNS Drugs; September 7, 2022
Author(s): Tina Nie & Hannah A. Blair
A review of inebilizumab treatment in NMOSD
Journal: Multiple Sclerosis and Related Disorders; August 26, 2021
Author(s): Eoin P. Flanagan a, Michael Levy b, Eliezer Katz c, Daniel Cimbora c, Jorn Drappa c, Maureen A. Mealy c, Dewei She c, Bruce A.C. Cree
Effects of inebilizumab treatment in NMOSD patients who have previously been on rituximab
Journal: Multiple Sclerosis Journal; October 1, 2021
Author(s): Mary Rensel, Aram Zabeti, Maureen A Mealy, Daniel Cimbora, Dewei She, Jorn Drappa, Eliezer Katz
Long-term efficacy and safety of inebilizumab in AQP4-positive NMOSD patients over at least 4 years
Journal: The New England Journal of Medicine; November 28, 2019
Author(s): Takashi Yamamura, Ingo Kleiter, Kazuo Fujihara, Jacqueline Palace, Benjamin Greenberg, Beata Zakrzewska-Pniewska, Francesco Patti, Ching-Piao Tsai, Albert Saiz, Hayato Yamazaki, Yuichi Kawata, Padraig Wright, Jerome De Seze
Efficacy and safety of satralizumab combined with immunosuppressants in seropositive or seronegative NMOSD
Journal: The Lancet Neurology; May 1, 2020
Author(s): Anthony Traboulsee, Benjamin M Greenberg, Jeffrey L Bennett, Lech Szczechowski, Edward Fox, Svitlana Shkrobot, Takashi Yamamura, Yusuke Terada, Yuichi Kawata, Padraig Wright, Athos Gianella-Borradori, Hideki Garren, Brian G Weinshenker
Safety and efficacy of satralizumab treatment alone in NMOSD
Journal: Neurology Neuroimmunology & Neuroinflammation; December 8, 2022
Author(s): Ingo Kleiter, Anthony Traboulsee, Jacqueline Palace, Takashi Yamamura, Kazuo Fujihara, Albert Saiz, Adil Javed, David Mayes, H-Christian von Büdingen, Gaelle Klingelschmitt, Daniela Stokmaier, Jeffrey L Bennett
Long-term efficacy of satralizumab in NMOSD patients testing positive for aquaporin-4 antibodies
